Abstract
Computational modeling shows that intra-arterial delivery is most efficient when the delivered drugs rapidly and avidly bind to the target site. The cell-penetrating peptide trans-activator of transcription (TAT) is a candidate carrier molecule that could mediate such specificity for brain tumor chemotherapeutics. To test this hypothesis we first performed in vitro studies testing the uptake of TAT by one primary and three potentially metastatic brain cancer cell lines (9L, 4T-1, LLC, SKOV-3). Then we performed in vivo studies in a rat model where TAT was delivered either intra-arterially (IA) or intravenously (IV) to 9L brain tumors. We observed robust uptake of TAT by all tumor cell lines in vitro. Flow cytometry and confocal microscopy revealed a rapid uptake of fluorescein-labeled TAT within 5 min of exposure to the cancer cells. IA injections done under transient cerebral hypoperfusion (TCH) generated a four-fold greater tumor TAT concentration compared to conventional IV injections. We conclude that it is feasible to selectively target brain tumors with TAT-linked chemotherapy by the IA-TCH method.
Similar content being viewed by others
References
Dobrzynska I, Skrzydlewska E, Figaszewski ZA (2013) Changes in electric properties of human breast cancer cells. J Membr Biol 246(2):161–166. doi:10.1007/s00232-012-9516-5
Dobrzynska I, Szachowicz-Petelska B, Darewicz B, Figaszewski ZA (2015) Characterization of human bladder cell membrane during cancer transformation. J Membr Biol 248(2):301–307. doi:10.1007/s00232-015-9770-4
Dobrzynska I, Szachowicz-Petelska B, Sulkowski S, Figaszewski Z (2005) Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol Cell Biochem 276(1–2):113–119. doi:10.1007/s11010-005-3557-3
Klahn M, Zacharias M (2013) Transformations in plasma membranes of cancerous cells and resulting consequences for cation insertion studied with molecular dynamics. Phys Chem Chem Phys 15(34):14427–14441. doi:10.1039/c3cp52085d
Ran S, Downes A, Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62(21):6132–6140
Szachowicz-Petelska B, Dobrzynska I, Skrodzka M, Darewicz B, Figaszewski ZA, Kudelski J (2013) Phospholipid composition and electric charge in healthy and cancerous parts of human kidneys. J Membr Biol 246(5):421–425. doi:10.1007/s00232-013-9554-7
Chen B, Le W, Wang Y, Li Z, Wang D, Ren L, Lin L, Cui S, Hu JJ, Hu Y, Yang P, Ewing RC, Shi D, Cui Z (2016) Targeting negative surface charges of cancer cells by multifunctional nanoprobes. Theranostics 6(11):1887–1898. doi:10.7150/thno.16358
Abbasi S, Paul A, Shao W, Prakash S (2012) Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv 2012:686108. doi:10.1155/2012/686108
Bilensoy E, Sarisozen C, Esendagli G, Dogan AL, Aktas Y, Sen M, Mungan NA (2009) Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm 371(1–2):170–176. doi:10.1016/j.ijpharm.2008.12.015
Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch KW, Dellian M (2006) Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther 5(1):89–96
Lu W, Wan J, Zhang Q, She Z, Jiang X (2007) Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int J Cancer 120(2):420–431
Xu F, Lu W, Wu H, Fan L, Gao X, Jiang X (2009) Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. J Drug Target 17(6):423–434
Zhao M, Chang J, Fu X, Liang C, Liang S, Yan R, Li A (2012) Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats. J Drug Target 20(5):416–421
Gupta B, Levchenko TS, Torchilin VP (2007) TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16(8):351–359
Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, Moochhala S, Kan L (2008) Polymeric micelles anchored with TAT for delivery of antibiotics across the blood–brain barrier. Biopolymers 90(5):617–623. doi:10.1002/bip.20998
Zelphati O, Uyechi LS, Barron LG, Szoka FC Jr (1998) Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1390(2):119–133
Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62(23):6831–6836
Mickan A, Sarko D, Haberkorn U, Mier W (2014) Rational design of CPP-based drug delivery systems: considerations from pharmacokinetics. Curr Pharm Biotechnol 15(3):200–209
Riina HA, Knopman J, Greenfield JP, Fralin S, Gobin YP, Tsiouris AJ, Souweidane MM, Boockvar JA (2010) Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Intervent Neuroradiol 16(1):71–76
Pile-Spellman J, Young WL, Joshi S, Duong DH, Vang MC, Hartmann A, Kahn RA, Rubin DA, Prestigiacomo CJ, Ostapkovich ND (1999) Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: technical case report. Neurosurgery 44(4):881–886 (discussion 886–887)
Hashimoto T, Young WL, Aagaard BD, Joshi S, Ostapkovich ND, Pile-Spellman J (2000) Adenosine-induced ventricular asystole to induce transient profound systemic hypotension in patients undergoing endovascular therapy: dose-response characteristics [In Process Citation]. Anesthesiology 93(4):998–1001
Joshi S, Wang M, Etu JJ, Suckow RF, Cooper TB, Feinmark SJ, Bruce JN, Fine RL (2007) Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol 86(2):123–132
Klopp CT, Alford TC, Bateman J, Berry GN, Winship T (1950) Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 132(4):811–832
Wilson CB (1976) Chemotherapy of brain tumors. Adv Neurol 15:361–367
Wilson CB (1964) Chemotherapy of brain tumors by continuous arterial infusion. Surgery 55:640–653
Levin VA, Wilson CB (1976) Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat Rep 60(6):719–724
Wilson CB, Gutin P, Boldrey EB, Drafts D, Levin VA, Enot KJ (1976) Single-agent chemotherapy of brain tumors. A five-year review. Arch Neurol 33(11):739–744
Mitsuki S, Diksic M, Conway T, Yamamoto YL, Villemure JG, Feindel W (1991) Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol 10(1):47–55
Tyler JL, Yamamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, Evans AC, Feindel W (1986) Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med 27(6):775–780
Rosenblum MK, Delattre JY, Walker RW, Shapiro WR (1989) Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 7(3):269–281
Tonn JC, Roosen K, Schachenmayr W (1991) Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas–a complication of both ACNU and BCNU? J Neurooncol 11(3):241–242
Kroll RA, Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means [Comments by Paul. Kornblith L, Pollay Michael, Pierre-Yves Dietrich and Nicolas de Tribolet, Berislav Zlokovic]. Neurosurgery 42(5):1083–1100
Neuwelt EA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Hill SA, Lewis SE, Ehle AL, Beyer CW Jr, Moore RJ (1979) Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery. Trans Am Neurol Assoc 104:256–260
Stewart DJ, Grahovac Z, Hugenholtz H, DaSilva V, Richard MT, Benoit B, Belanger G, Russell N (1993) Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. J Neurooncol 17(1):71–79
Newton HB, Slivka MA, Volpi C, Bourekas EC, Christoforidis GA, Baujan MA, Slone W, Chakeres DW (2003) Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 61(1):35–44
Cloughesy TF, Gobin YP, Black KL, Vinuela F, Taft F, Kadkhoda B, Kabbinavar F (1997) Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 35(2):121–131
Vance RB, Pittisapu J, Kapp JP (1986) Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas. J Neurooncol 4(2):151–154
Oldfield EH, Dedrick RL, Yeager RL, Clark WC, DeVroom HL, Chatterji DC, Doppman JL (1985) Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. J Neurosurg 63(5):726–732
D’Aliberti G, Talamonti G, Versari PP, Todaro C, Bizzozero L, Arena O, Collice M (1997) Comparison of pediatric and adult cerebral arteriovenous malformations. J Neurosurg Sci 41(4):331–336
Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA (2011) Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma Clinical article. J Neurosurg 114(3):624–632. doi:10.3171/2010.9.Jns101223
Shin BJ, Burkhardt JK, Riina HA, Boockvar JA (2012) Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 23(2):323–329
Cooke JN, Ellis JA, Hossain S, Nguyen J, Bruce JN, Joshi S (2016) Computational pharmacokinetic rationale for intra-arterial delivery to the brain. Drug Deliv Transl Res. doi:10.1007/s13346-016-0319-6
Dedrick RL (1988) Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst 80(2):84–89
Joshi S, Wang M, Etu JJ, Nishanian EV, Pile-Spellman J (2006) Cerebral blood flow affects dose requirements of intracarotid propofol for electrocerebral silence. Anesthesiology 104(2):290–298
Joshi S, Wang M, Etu JJ, Pile-Spellman J (2005) Reducing cerebral blood flow increases the duration of electroencephalographic silence by intracarotid thiopental. Anesthesia Analgesia 101(3):851–858
Joshi S, Singh-Moon RP, Ellis JA, Chaudhuri DB, Wang M, Reif R, Bruce JN, Bigio IJ, Straubinger RM (2014) Cerebral hypoperfusion-assisted intraarterial deposition of liposomes in normal and glioma-bearing rats. Neurosurgery NIHMS 624641 (in press)
Joshi S, Singh-Moon RP, Wang M, Chaudhuri DB, Holcomb M, Straubinger NL, Bruce JN, Bigio IJ, Straubinger RM (2014) Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue. J Neurooncol. doi:10.1007/s11060-014-1421-6
Ellis JA, Cooke J, Singh-Moon RP, Wang M, Bruce JN, Emala CW, Bigio IJ, Joshi S (2016) Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. J Neurooncol 130(3):449–454. doi:10.1007/s11060-016-2253-3
Joshi S, Cooke JR, Chan DK, Ellis JA, Hossain SS, Singh-Moon RP, Wang M, Bigio IJ, Bruce JN, Straubinger RM (2016) Liposome size and charge optimization for intraarterial delivery to gliomas. Drug Deliv Transl Res 6(3):225–233. doi:10.1007/s13346-016-0294-y
Nguyen J, Cooke JR, Ellis JA, Deci M, Emala CW, Bruce JN, Bigio IJ, Straubinger RM, Joshi S (2016) Cationizable lipid micelles as vehicles for intraarterial glioma treatment. J Neurooncol. doi:10.1007/s11060-016-2088-y
Joshi S, Singh-Moon RP, Ellis JA, Chaudhuri DB, Wang M, Reif R, Bruce JN, Bigio IJ, Straubinger RM (2015) Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats. Neurosurgery 76(1):92–100. doi:10.1227/NEU.0000000000000552
Pile-Spellman J, Young WL, Joshi S, Duong H, Vang MC, Hartmann A, Kahn RA, Rubin DA, Prestigiacomo CJ, Ostapkovich ND (1999) Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: technical case report. Neurosurgery 44(4):881–886 (discussion 886–887)
Hashimoto T YW, Davis CC, Joshi S, Ostapkovich ND (1999) Dose-response characteristics of adenosine when used for cardiac pause for deliberate systemic hypotension (Abstract #807). J Neurosurg Anesthesiol 11:327
Hashimoto T, Young WL, Aagaard BD, Joshi S, Ostapkovich ND, Pile-Spellman J (2000) Adenosine-induced ventricular asystole to induce transient profound systemic hypotension in patients undergoing endovascular therapy. Dose-response characteristics. Anesthesiology 93(4):998–1001
Yang X, Page M (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res 7(12):619–624
Wang RH, Bai J, Deng J, Fang CJ, Chen X (2017) TAT-modified gold nanoparticle carrier with enhanced anticancer activity and size effect on overcoming multidrug resistance. ACS Appl Mater Interfaces 9(7):5828–5837. doi:10.1021/acsami.6b15200
Banks WA, Robinson SM, Nath A (2005) Permeability of the blood–brain barrier to HIV-1 Tat. Exp Neurol 193(1):218–227. doi:10.1016/j.expneurol.2004.11.019
Nguyen J, Hossain SS, Cooke JRN, Ellis JA, Deci MB, Emala CW, Bruce JN, Bigio IJ, Straubinger RM, Joshi S (2017) Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas. J Neurooncol 133(1):77–85. doi:10.1007/s11060-017-2429-5
Aziz HA, Boutrid H, Murray TG, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA (2010) Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. Retina 30(4 Suppl):S63-65. doi:10.1097/IAE.0b013e3181cbda0f
Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115(8):1398–1404. doi:10.1016/j.ophtha.2007.12.014
Funding
The funding was provided by National Cancer Institute at the National Institutes of Health (Grant No. RO1-CA-138643).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joshi, S., Cooke, J.R.N., Ellis, J.A. et al. Targeting brain tumors by intra-arterial delivery of cell-penetrating peptides: a novel approach for primary and metastatic brain malignancy. J Neurooncol 135, 497–506 (2017). https://doi.org/10.1007/s11060-017-2615-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-017-2615-5